Login to Your Account

Terns nabs three early-stage Lilly NASH candidates for China-first development

By Shannon Ellis
Staff Writer

Wednesday, April 11, 2018

SHANGHAI – One-year-old Terns Pharmaceuticals will seed its pipeline with three candidates for nonalcoholic steatohepatitis (NASH), having acquired global development and commercialization rights from Eli Lilly and Co., of Indianapolis. Terns intends to take a China-first strategy for the development and registration of these candidates for liver disease while remaining open to global opportunities.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription